Salvinorin-A induces intense dissociative effects, blocking external sensory perception and modulating interoception and sense of body ownership in humans

International Journal of Neuropsychopharmacology

Volumn 18, Issue 12, 2015, Pages 1-14

  Maqueda, Ana Elda ^a   Valle, Marta ^a,b,c,d   Addy, Peter H ^e,f   Antonijoan, Rosa Maria ^b,c,d   Puntes, Montserrat ^b   Coimbra, Jimena ^b   Ballester, Maria Rosa ^b   Garrido, Maite ^b   González, Mireia ^b   Claramunt, Judit ^b   Barker, Steven ^g   Johnson, Matthew W ^h   Griffiths, Roland R ^h   Riba, Jordi ^a,b,c,d  

^a BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^e VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g LOUISIANA STATE UNIVERSITY   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Body ownership; Dissociative effects; Dynorphins; Human; Interoception; Kappa opioid receptor; Salvia divinorum. salvinorin A

Indexed keywords

PLACEBO; SALVINORIN A; CLERODANE DERIVATIVE; PSYCHOTROPIC AGENT;

ADULT; AFFECT; ALTERED STATES OF CONSCIOUSNESS; ARTICLE; ASSESSMENT OF HUMANS; BODY IMAGE; COGNITION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HALLUCINOGEN RATING SCALE; HUMAN; INTEROCEPTION; MALE; MULTIDIMENSIONAL ASSESSMENT FOR INTEROCEPTIVE AWARENESS; NORMAL HUMAN; PERCEPTION; PRIORITY JOURNAL; SENSATION; VISION; CHEMICALLY INDUCED; CONSCIOUSNESS; DOSE RESPONSE; DRUG EFFECTS; HALLUCINATION; HEARING; ORGANIZATION AND MANAGEMENT; SELF CONCEPT; VERBAL COMMUNICATION; YOUNG ADULT;

ADULT; AUDITORY PERCEPTION; CONSCIOUSNESS; DITERPENES, CLERODANE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALLUCINATIONS; HUMANS; INTEROCEPTION; MALE; NARRATION; OWNERSHIP; PSYCHOTROPIC DRUGS; SELF CONCEPT; VISUAL PERCEPTION; YOUNG ADULT;

EID: 84960133390     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyv065     Document Type: Article

References (43)

1. Addy PH (2012) Acute and post-acute behavioral and psychological effects of salvinorin A in humans. Psychopharmacology (Berl) 220:195-204.
2. Addy PH, Garcia-Romeu A, Metzger M, Wade J (2015) The subjective experience of acute, experimentally-induced Salvia divinorum inebriation. J Psychopharmacol 29:426-435.
3. Baggott MJ, Erowid E, Erowid F, Galloway GP, Mendelson J (2010) Use patterns and self-reported effects of Salvia divinorum: an internet-based survey. Drug Alcohol Depend 111:250-256.
4. Blanke O, Ortigue S, Landis T, Seeck M (2002) Stimulating illusory own-body perceptions. Nature 419:269-270.
5. Bücheler R, Gleiter CH, Schwoerer P, Gaertner I (2005) Use of nonprohibited hallucinogenic plants: increasing relevance for public health? A case report and literature review on the consumption of Salvia divinorum (Diviner's Sage). Pharmacopsychiatry 38:1-5.
6. Chavkin C (2013) Dynorphin - still an extraordinarily potent opioid peptide. Mol Pharmacol 83:729-736.
7. Craig ADB (2009) How do you feel - now? The anterior insula and human awareness. Nat Rev Neurosci 10:59-70.
8. Dittrich A (1998) The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 31(Supp 2):80-84.
9. González D, Riba J, Bouso JC, Gómez-Jarabo G, Barbanoj MJ (2006) Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend 85:157-162.
10. Griffiths RR, Richards WA, McCann U, Jesse R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 187:268-283; disc 284-292.
11. Hanes KR (2001) Antidepressant effects of the herb Salvia divinorum: a case report. J Clin Psychopharmacol 21:634-635.
12. Johnson MW, MacLean KA, Reissig CJ, Prisinzano TE, Griffiths RR (2011) Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend 115:150-155.
13. Lamas X, Farré M, Llorente M, Camí J (1994) Spanish version of the 49-item short form of the Addiction Research Center Inventory (ARCI). Drug Alcohol Depend 35:203-209.
14. Le Merrer J, Becker JAJ, Befort K, Kieffer BL (2009) Reward processing by the opioid system in the brain. Physiol Rev 89:1379-1412.
15. Luke DP, Terhune DB (2013) The induction of synaesthesia with chemical agents: a systematic review. Front Psychol 4:753.
16. MacLean KA, Johnson MW, Reissig CJ, Prisinzano TE, Griffiths RR (2013) Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects. Psychopharmacology (Berl) 226:381-392.
17. Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971) Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12:245-258.
18. Mehling WE, Price C, Daubenmier JJ, Acree M, Bartmess E, Stewart A (2012) The Multidimensional Assessment of Interoceptive Awareness (MAIA). PLOS One 7:e48230.
19. Mehling WE, Daubenmier J, Price CJ, Acree M, Bartmess E, Stewart AL (2013) Self-reported interoceptive awareness in primary care patients with past or current low back pain. J Pain Res 6:403-418.
20. Ott J (1995) Ethnopharmacognosy and human pharmacology of Salvia divinorum and salvinorin A. Curare 18:103-129.
21. Paulus MP, Stein MB (2010) Interoception in anxiety and depression. Brain Struct Funct 214:451-463.
22. Prisinzano TE (2005) Psychopharmacology of the hallucinogenic sage Salvia divinorum. Life Sci 78:527-531.
23. Raichle ME (2011) The restless brain. Brain Connect 1:3-12. Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA
24. Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL (2001) A default mode of brain function. Proc Natl Acad Sci USA 98:676-682.
25. Ranganathan M, Schnakenberg A, Skosnik PD, Cohen BM, Pittman B, Sewell RA, D'Souza DC (2012) Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans. Biol Psychiatry 72:871-879.
26. Raos VC, Dermon CR, Savaki HE (1995) Functional anatomy of the thalamic centrolateral nucleus as revealed with the [14C] deoxyglucose method following electrical stimulation and electrolytic lesion. Neuroscience 68:299-313.
27. Riba J, Rodríguez-Fornells A, Barbanoj MJ (2002) Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively. Psychopharmacology (Berl) 165:18-28.
28. Riba J, Rodríguez-Fornells A, Strassman RJ, Barbanoj MJ (2001a) Psychometric assessment of the Hallucinogen Rating Scale. Drug Alcohol Depend 62:215-223.
29. Riba J, Rodríguez-Fornells A, Urbano G, Morte A, Antonijoan R, Montero M, Callaway JC, Barbanoj MJ (2001b) Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology (Berl) 154:85-95.
30. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB (2002) Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci USA 99:11934-11939.
31. Schmidt MD, Schmidt MS, Butelman ER, Harding WW, Tidgewell K, Murry DJ, Kreek MJ, Prisinzano TE (2005) Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates. Synap N Y N 58:208-210.
32. Schwarzer C (2009) 30 years of dynorphins - new insights on their functions in neuropsychiatric diseases. Pharmacol Ther 123:353-370.
33. Seisdedos N (2002) STAI Cuestionario de ansiedad estado-rasgo. Adaptación española del cuestionario y redacción del manual. Madrid, Spain: TEA Ediciones, SA.
34. Siebert DJ (1994) Salvia divinorum and salvinorin A: new pharmacologic findings. J Ethnopharmacol 43:53-56.
35. Simonin F, Gaveriaux-Ruff C, Befort K, Matthes H, Lannes B, Micheletti G, Mattei MG, Charron G, Bloch B, Kieffer B (1995) kappa-Opioid receptor in humans: cDNA and genomic cloning, chromosomal assignment, functional expression, pharmacology, and expression pattern in the central nervous system. Proc Natl Acad Sci USA 92:7006-7010.
36. Spielberger CD, Gorsuch RL, Lushene RE (1970) Manual for the state-trait anxiety inventory. Palo Alto, CA: Consulting Psychologists.
37. Stiefel KM, Merrifield A, Holcombe AO (2014) The claustrum's proposed role in consciousness is supported by the effect and target localization of Salvia divinorum. Front Integr Neurosci 8:20.
38. Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R (1994) Doseresponse study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 51:98-108.
39. Tejeda HA, Shippenberg TS, Henriksson R (2012) The dynorphin/κ-opioid receptor system and its role in psychiatric disorders. Cell Mol Life Sci 69:857-896.
40. Valdés LJ, Díaz JL, Paul AG (1983) Ethnopharmacology of ska María Pastora (Salvia divinorum, Epling and Játiva-M.). J Ethnopharmacol 7:287-312.
41. Van der Werf YD, Witter MP, Groenewegen HJ (2002) The intralaminar and midline nuclei of the thalamus. Anatomical and functional evidence for participation in processes of arousal and awareness. Brain Res Brain Res Rev 39:107-140.
42. Verdejo-Garcia A, Clark L, Dunn BD (2012) The role of interoception in addiction: a critical review. Neurosci Biobehav Rev 36:1857-1869.
43. Walsh SL, Strain EC, Abreu ME, Bigelow GE (2001) Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans. Psychopharmacology (Berl) 157:151-162.